Table 1. Correlation between IQGAP3 expression and clinical parameters in patients with GBMLGG in the TCGA-GBMLGG cohort.
| Characteristic | IQGAP3 (Low) | IQGAP3 (High) | p-value |
|---|---|---|---|
| n | 348 | 348 | |
| WHO grade, n (%) | <0.001 | ||
| G2 | 182 (28.7%) | 42 (6.6%) | |
| G3 | 113 (17.8%) | 130 (20.5%) | |
| G4 | 15 (2.4%) | 153 (24.1%) | |
| IDH status, n (%) | <0.001 | ||
| WT | 43 (6.3%) | 203 (29.6%) | |
| Mut | 301 (43.9%) | 139 (20.3%) | |
| 1p/19q codeletion, n (%) | <0.001 | ||
| codel | 127 (18.4%) | 44 (6.4%) | |
| non-codel | 220 (31.9%) | 298 (43.3%) | |
| Primary therapy outcome, n (%) | <0.001 | ||
| PD | 46 (10%) | 66 (14.3%) | |
| SD | 91 (19.7%) | 56 (12.1%) | |
| PR | 49 (10.6%) | 15 (3.2%) | |
| CR | 99 (21.4%) | 40 (8.7%) | |
| Gender, n (%) | 0.319 | ||
| Female | 156 (22.4%) | 142 (20.4%) | |
| Male | 192 (27.6%) | 206 (29.6%) | |
| Age, n (%) | <0.001 | ||
| <=60 | 315 (45.3%) | 238 (34.2%) | |
| >60 | 33 (4.7%) | 110 (15.8%) | |
| Histological type, n (%) | <0.001 | ||
| Astrocytoma | 116 (16.7%) | 79 (11.4%) | |
| Glioblastoma | 15 (2.2%) | 153 (22%) | |
| Oligoastrocytoma | 84 (12.1%) | 50 (7.2%) | |
| Oligodendroglioma | 133 (19.1%) | 66 (9.5%) | |
| OS event, n (%) | <0.001 | ||
| Alive | 285 (40.9%) | 139 (20%) | |
| Dead | 63 (9.1%) | 209 (30%) | |
| DSS event, n (%) | <0.001 | ||
| Alive | 286 (42.4%) | 145 (21.5%) | |
| Dead | 56 (8.3%) | 188 (27.9%) | |
| PFI event, n (%) | <0.001 | ||
| Alive | 235 (33.8%) | 115 (16.5%) | |
| Dead | 113 (16.2%) | 233 (33.5%) | |
| Age, median (IQR) | 39 (32, 51) | 53 (39, 63) | <0.001 |